Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 8.26 -3.84% -0.33
BCRX closed down 3.84 percent on Friday, December 14, 2018, on 85 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical BCRX trend table...

Date Alert Name Type % Chg
Dec 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Dec 14 Stochastic Reached Oversold Weakness 0.00%
Dec 14 Strong but Oversold Other 0.00%
Dec 14 Oversold Stochastic Weakness 0.00%
Dec 13 Fell Below 20 DMA Bearish -3.84%
Dec 13 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.84%
Dec 13 Wide Bands Range Expansion -3.84%
Dec 12 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -7.61%
Dec 12 NR7 Range Contraction -7.61%
Dec 12 Wide Bands Range Expansion -7.61%

Older signals for BCRX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company's product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.7
52 Week Low 4.25
Average Volume 591,614
200-Day Moving Average 6.4675
50-Day Moving Average 7.827
20-Day Moving Average 8.814
10-Day Moving Average 8.882
Average True Range 0.5221
ADX 24.31
+DI 18.1124
-DI 17.5953
Chandelier Exit (Long, 3 ATRs ) 8.133699999999999
Chandelier Exit (Short, 3 ATRs ) 8.3763
Upper Bollinger Band 9.8799
Lower Bollinger Band 7.7481
Percent B (%b) 0.24
BandWidth 24.186521
MACD Line 0.2398
MACD Signal Line 0.3647
MACD Histogram -0.1249
Fundamentals Value
Market Cap 664.33 Million
Num Shares 80.4 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -13.32
Price-to-Sales 11.43
Price-to-Book 13.91
PEG Ratio -0.28
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.12
Resistance 3 (R3) 9.18 8.97 8.97
Resistance 2 (R2) 8.97 8.75 8.93 8.92
Resistance 1 (R1) 8.61 8.61 8.51 8.55 8.88
Pivot Point 8.40 8.40 8.34 8.36 8.40
Support 1 (S1) 8.04 8.18 7.94 7.98 7.64
Support 2 (S2) 7.83 8.04 7.79 7.60
Support 3 (S3) 7.47 7.83 7.55
Support 4 (S4) 7.41